

A study to evaluate the effect of ETAZEO supplementation on sleep quality

Submission date 18/06/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 27/06/2024	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 20/06/2024	Condition category Nervous System Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

The health impact of improved sleep and reduced snoring cannot be underestimated. Chronic sleeplessness and other related sleep disorders have been associated with an increased risk of developing various health conditions such as hypertension, coronary artery disease, and stroke. This scientific research study is designed to test the impact of ETAZEO®, a supplement containing fermented *Salvia Officinalis* (sage) metabolites, on sleep and snoring in Asian participants over 4 weeks.

Who can participate?

Healthy non-smoker Asian subjects aged between 25 and 65 years old (inclusive) with the presence of chronically disturbed sleep (PSQI >5)

What does the study involve?

Participants will be randomly assigned to a once-daily ETAZEO® supplement or a placebo /dummy supplement for 4 weeks.

What are the possible benefits and risks of participating:

Possible benefits are an improvement in skin health. No risks are expected.

Where is the study run from?

INNOVATION LABO Sciences Co., Ltd (Japan)

When is the study starting and how long is it expected to run for?

June 2023 to July 2023

Who is funding the study?

INNOVATION LABO Sciences Co., Ltd (Japan)

Who is the main contact?

Dr Yuki Ikeda, development@innovationlabo.com (Japan)

Contact information

Type(s)

Scientific

Contact name

Dr Yuki Ikeda

ORCID ID

<https://orcid.org/0000-0001-6067-4574>

Contact details

Shintomi HJ bldg 5F

1-12-7 Shintomi

Tokyo

Japan

104-0041

+81 335525335

development@innovationlabo.com

Type(s)

Principal investigator

Contact name

Dr Olivier Le Moal

Contact details

1 place marie Curie

Annecy

France

74000

+33 (0)4 50 33 08 63

innovation@mayor-invivo.com

Type(s)

Public

Contact name

Mrs Celine Klotz

Contact details

Shintomi HJ bldg 5F

1-12-7 Shintomi

Tokyo

Japan

104-0041

+81 335525335

tokyo@innovationlabo.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

SL/IL 22-0456

Study information

Scientific Title

Double-blind placebo-controlled clinical study to evaluate the effect of supplementation with ETAZE0 during 4 weeks in improving sleep quality in healthy Asian adults suffering from insomnia

Study objectives

ETAZE0 is more efficient than a placebo in improving sleep quality

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 30/11/2022, Japanese Society of Anti-Aging Nutrition (JAAN) (Ginza, Chuo-ku, Tokyo, 104-0061, Japan; +81 3 3552 5277; coordinator@jaan.jp), ref: ILOS22633-K148

Study design

Interventional double-blind placebo-controlled single-center randomized clinical trial

Primary study design

Interventional

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Improvement of sleep quality in participants with insomnia

Interventions

This study investigates 4 weeks of daily supplementation with ETAZE0 (250 mg capsule) or a placebo (dextrin, 250 mg capsule) taken orally in the evening before sleep. Block randomization was used to allocate participants to each group.

Block randomization is used to divide potential patients into m blocks of size $2n$, randomize each block such that n patients are allocated to A and n to B then choose the blocks randomly. This method ensures equal treatment allocation within each block if the complete block is used.

Intervention Type

Supplement

Primary outcome(s)

Change in sleep score measured using the Pittsburgh Sleep Quality Index (PSQI) questionnaire at baseline and week 4

Key secondary outcome(s))

Change in snoring score measured using the Snoring Severity Scale (SSS) questionnaire at baseline and week 4

Completion date

31/07/2023

Eligibility

Key inclusion criteria

1. Healthy non-smoker Asian male and female subjects between 25-65 years old (inclusive)
2. Presence of chronic disturbed sleep (PSQI >5)
3. Presence of chronic snoring. A patient is considered a chronic snorer if his/her bedmate /roommate reported snoring more than 5 days per week and if this is corroborated by medical analysis performed in the patient's own home. The result of the respiratory polygraphy should indicate the presence of snoring during at least 30% of the nocturnal period.
4. Have a regular roommate or bedmate to submit information
5. Subjects available during the whole period of study (1 month)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

25 years

Upper age limit

65 years

Sex

All

Total final enrolment

40

Key exclusion criteria

1. Subjects with sleep apnoea
2. High-risk professions and/or controlling dangerous machines
3. Moderate or severe somnolence during day time
4. Coronary cardiopathy, acute vascular disease (less than three months), chronic and severe obstructive pulmonary disease, and chronic treatment with theophyllines
5. Temporo-mandibular joint problems or periodontitis

6. Mandibular protrusion capacity less than 6 mm and/or less than 10 teeth in each jaw
7. Severe cognitive disorders and/or patients whose answers to the questionnaires will be altered by chronic and severe diseases
8. Pregnancy (since the third month of pregnancy to 3 months after birth delivery)
9. Patients on prolonged medication (more than 6 weeks) with sleep medication, corticosteroids, antidepressants, anticholinergics, antipsychotic drugs, etc. or any other drugs that may have an influence on the outcome of the study
10. Pregnant/lactating women
11. Subjects who cannot agree to refrain from alcohol consumption during the study period
12. Alcoholics and/or drug abusers
13. Subjects having history of psychiatric disorders that may impair the ability to provide written informed consent
14. Patients who have completed participation in any other clinical trials during the past 3 months
15. Any other conditions that the Principal Investigator thinks may jeopardize the study outcomes

Date of first enrolment

21/02/2023

Date of final enrolment

13/04/2023

Locations

Countries of recruitment

France

Study participating centre**Mayor In-vivo**

1, place Marie Curie

Annecy

France

74000

Sponsor information

Organisation

INNOVATION LABO Sciences Co., Ltd

Funder(s)

Funder type

Industry

Funder Name

INNOVATION LABO Sciences Co., Ltd

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Yuki Ikeda, development@innovationlabo.com. Anonymised IPD will be available upon publication of results and for a period of 2 years. Consent from participants was required and obtained.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes